Page 48 - COVID-19-Mortality-review-in-Malaysia-and-updates-on-clinical-management-of-COVID-19

Reference

1. Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-
Baildon M, Klein M, Weinberger T. Elevated levels of interleukin-6 and CRP

predict the need for mechanical ventilation in COVID-19. Journal of Allergy
and Clinical Immunology. 2020 May 18.

2. Sciascia S, Aprà F, Baffa A, Baldovino S, Boaro D, Boero R, Bonora S,
Calcagno A, Cecchi I, Cinnirella G, Converso M. Pilot prospective open,
single-arm multicentre study on off-label use of tocilizumab in severe

patients with COVID-19. Clin Exp Rheumatol. 2020 May 1;38(3):529-32.
3. Coronavirus: Dexamethasone proves first life-saving drug By Michelle
Roberts, Health editor, BBC News online. 2020 June 16.

https://www.bbc.com/news/health-53061281
4. Personal communication on Twitter by @PeterHorby. 2020 June 16. https://
twitter.com/PeterHorby/status/1272868886430564364?s=20

5. Yan D, Liu XY, Zhu YN, Huang L, Dan BT, Zhang GJ, Gao YH. Factors
associated with prolonged viral shedding and impact of lopinavir-ritonavir

treatment in hospitalized non-critically ill patients with SARS-CoV-2
infection. European Respiratory Journal. 2020 Jan 1.
6. Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, Ng YY, Lo J, Chan J,

Tam AR, Shum HP. Triple combination of interferon beta-1b, lopinavir–
ritonavir, and ribavirin in the treatment of patients admitted to hospital

with COVID-19: an open-label, randomised, phase 2 trial. The Lancet. 2020
May 30;395(10238):1695-704.
7. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC,

Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D.
Remdesivir for the treatment of Covid-19—preliminary report. New

England Journal of Medicine. 2020 May 22.
8. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y, Shen
C. Experimental treatment with favipiravir for COVID-19: an open-label

control study. Engineering. 2020 Mar 18.